X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/rigel-reports-second-quarter-2024-financial-results-and-provides-business-update-302215852.html
https://endpts.com/blueprint-to-pull-gavreto-in-certain-markets-shelve-egfr-programs-as-it-focuses-on-ayvakit-launch/
https://endpts.com/genentech-blueprint-tout-full-approval-for-gavreto-in-rare-type-of-lung-cancer/
https://www.ema.europa.eu/en/documents/overview/gavreto-epar-medicine-overview_en.pdf
https://www.fiercepharma.com/pharma/roche-pulls-gavreto-accelerated-approval-blueprint-severance-confirmatory-trial-turns
https://www.onclive.com/view/genentech-withdraws-us-indication-for-pralsetinib-in-advanced-or-metastatic-ret-medullary-thyroid-cancer
https://www.fiercepharma.com/pharma/after-splashing-1b-roche-returns-lagging-cancer-drug-gavreto-blueprint
https://www.newswise.com/articles/pralsetinib-achieves-tissue-agnostic-benefits-for-patients-with-ret-gene-fusions
https://www.globenewswire.com/news-release/2021/11/19/2338282/0/en/European-Commission-approves-Roche-s-Gavreto-pralsetinib-for-the-treatment-of-adults-with-RET-fusion-positive-advanced-non-small-cell-lung-cancer.html
https://www.prnewswire.com/news-releases/blueprint-medicines-reports-third-quarter-2021-financial-results-301410584.html
https://www.raps.org/news-and-articles/news-articles/2021/9/euro-roundup-chmp-recommends-drugs-from-biogen-and
https://www.globenewswire.com/news-release/2021/09/17/2299002/0/en/Roche-receives-positive-CHMP-opinion-for-Gavreto-pralsetinib-for-the-treatment-of-adults-with-RET-fusion-positive-advanced-non-small-cell-lung-cancer.html
https://endpts.com/eli-lilly-blazes-new-trail-for-ret-inhibitor-ginning-up-a-response-in-9-solid-tumor-types-in-early-data/
http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-fda-approval-gavretotm-0
https://www.catalent.com/catalent-news/catalent-signs-commercial-supply-agreement-with-blueprint-medicines-following-fda-approval-of-gavreto-pralsetinib/#:~:text=SOMERSET%2C%20N.J.%20%E2%80%93%20November%2023%2C,commercial%20supply%20agreement%20with%20Blueprint
https://www.biospace.com/article/fda-action-alert-blueprint-liquidia-revance-rhythm-and-merck/?s=71
https://www.prnewswire.com/news-releases/blueprint-medicines-reports-arrow-trial-data-at-esmo-virtual-congress-2020-demonstrating-durable-clinical-benefits-of-gavreto-pralsetinib-in-patients-with-advanced-ret-mutant-medullary-thyroid-cancer-301134311.html
https://www.biospace.com/article/releases/pantherx-rare-pharmacy-selected-by-blueprint-medicines-to-distribute-gavreto-pralsetinib-for-the-treatment-of-adults-with-metastatic-ret-fusion-positive-non-small-cell-lung-cancer-nsclc-/
http://www.pharmafile.com/news/558554/genetech-scores-sixth-fda-approval-lung-cancer-gavreto
http://www.pharmafile.com/news/558554/genetech-scores-sixth-fda-approval-lung-cancer-gavreto
https://www.fiercepharma.com/marketing/blueprint-roche-take-lilly-fda-approval-for-ret-cancer-drug-gavreto
https://www.prnewswire.com/news-releases/blueprint-medicines-announces-submission-of-new-drug-application-to-fda-for-pralsetinib-for-the-treatment-of-advanced-ret-mutant-and-ret-fusion-positive-thyroid-cancers-301086412.html
http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-submission-new-drug-application
https://www.prnewswire.com/news-releases/blueprint-medicines-announces-data-presentations-highlighting-significant-progress-in-advancing-ret-altered-cancer-and-systemic-mastocytosis-programs-301059013.html
https://www.biopharmadive.com/news/blueprint-submit-pralsetinib-ret-lung-cancer-lilly/570048/
https://www.biopharmadive.com/news/blueprint-submit-pralsetinib-ret-lung-cancer-lilly/570048/
https://www.biopharmadive.com/news/blueprint-submit-pralsetinib-ret-lung-cancer-lilly/570048/
Market Place
Share 
